StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
OCA.AX$0.60-6.25%
Fair $0.60+0.0%

OCA.AX

Oceania Healthcare Limited

Healthcare / Medical Care FacilitiesASX

$0.60

-0.04 (-6.25%)

Fairly Valued+0.0%Fair Value $0.60Fund rank 34/100 · Data gapFallback financials|
SA 35/D
F-Score: 2/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 25% · confianza 25%

FCF escenarios

weak_data · normalized FCF $70.5M · quality 61.7/100

Data gap 34/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 57/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

35/100

D

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is 0.0%, below the 5% threshold
Thesis & Journal · OCA.AXLocal privado en este navegador · Oceania Healthcare Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$437M

P/E

3000.0x

↑

EV/EBITDA

23.0x

↑

ROE

0.0%

↓

Gross Margin

100.0%

↑

Debt/Equity

0.45

↑
52-Week Range$1
$1$1

TradingView lightweight chart

OCA.AX price, volumen y niveles de valoración

Último $0.600Periodo -18.9%
Fair value: $0.600

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2023–2026 · 3 años de histórico normalizado

Revenue CAGR

+2.6%

FCF CAGR

+116.0%

FCF margin

56.7%

FCF / Net income

1273.73x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $267.1M · net income $119000.0 · FCF $151.6M

2023-FY → 2026-FY

Gross margin

100.0%+0.0% pts

Operating margin

-5.7%-5.5% pts

Net margin

0.0%-6.2% pts

FCF margin

56.7%+50.7% pts
MetricTTM
2026
2025
2024
2023
Income Statement
Revenue$267.1M$267.1M$260.6M$265.5M$247.2M
Net Income$119000.00$119000.00$30.4M$31.5M$15.4M
EBITDA$41.1M$41.1M$68.1M$63.4M$43.8M
EPS0.000.000.040.040.02
Gross Margin100.0%100.0%100.0%100.0%100.0%
Operating Margin-5.7%-5.7%-8.0%-3.3%-0.2%
Net Margin0.0%0.0%11.7%11.9%6.2%
Balance Sheet
Debt/Equity0.450.450.580.630.58
Current Ratio0.120.12———
Cash Flow
Free Cash Flow$151.6M$151.6M$70.5M$33.4M$15.0M
Returns
ROE0.0%0.0%2.8%3.1%1.6%
Valuation
P/E3000.003000.0013.6913.3031.36
EV/EBITDA22.9822.9815.3916.8523.85
P/B0.370.370.380.410.51
Growth & Yield
Revenue Growth2.5%2.5%-1.8%7.4%—
EPS Growth-99.5%-99.5%-4.5%100.0%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

543.3%

muy exigente

EPS terminal req.

$0.05

Spread vs growth

-642.8%

5Y implied EPS CAGR

217.4%

muy exigente

EPS terminal req.

$0.06

Spread vs growth

-316.9%

10Y implied EPS CAGR

86.9%

muy exigente

EPS terminal req.

$0.10

Spread vs growth

-186.4%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +3.4%

Total return

+3.4%

Start / end P/E

13.8x → 3000.0x

EPS bridge

0.04 → 0.00

Residual

-21521.2%

EPS growth-99.5%
Multiple rerating+21624.1%
Dividend+0.0%
Residual / FX / buybacks / cross-term-21521.2%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.